BIMEL is a key effector molecule in oxidative stress-mediated apoptosis in acute myeloid leukemia cells when combined with arsenic trioxide and buthionine sulfoximine

BMC Cancer

Yukie Tanaka³  Takayuki Komatsu²  Hiroko Shigemi¹  Takahiro Yamauchi¹  Yutaka Fujii³ 

[1] Department of Hematology and Oncology, Faculty of Medical Sciences, University of Fukui, 23-3 Shimoaizuki, Matsuoka, Eiheiji, Fukui, Japan

[2] Department of Microbiology and Immunology, School of Medicine, Aichi Medical University, 1-1 Yazako-Karimata, Nagakute, Aichi, Japan

[3] Department of Molecular Biology and Chemistry, Faculty of Medical Sciences University of Fukui, 23-3 Shimoaizuki, Matsuoka, Eiheiji, Fukui, Japan

关键词: BAX;    MCL1;    BIM_EL;    Mitochondrial apoptosis;    Buthionine sulfoximine;    Arsenic trioxide;   

Others  :  859135
DOI  :  10.1186/1471-2407-14-27

 received in 2013-09-17, accepted in 2014-01-10,  发布年份 2014

【 摘 要 】

s

Background

Arsenic trioxide (ATO) is reported to be an effective therapeutic agent in acute promyelocytic leukemia (APL) through inducing apoptotic cell death. Buthionine sulfoximine (BSO), an oxidative stress pathway modulator, is suggested as a potential combination therapy for ATO-insensitive leukemia. However, the precise mechanism of BSO-mediated augmentation of ATO-induced apoptosis is not fully understood. In this study we compared the difference in cell death of HL60 leukemia cells treated with ATO/BSO and ATO alone, and investigated the detailed molecular mechanism of BSO-mediated augmentation of ATO-induced cell death.

Methods

HL60 APL cells were used for the study. The activation and expression of a series of signal molecules were analyzed with immunoprecipitation and immunoblotting. Apoptotic cell death was detected with caspases and poly (ADP-ribose) polymerase activation. Generation of intracellular reactive oxygen species (ROS) was determined using a redox-sensitive dye. Mitochondrial outer membrane permeabilization was observed with a confocal microscopy using NIR dye and cytochrome c release was determined with immunoblotting. Small interfering (si) RNA was used for inhibition of gene expression.

Results

HL60 cells became more susceptible to ATO in the presence of BSO. ATO/BSO-induced mitochondrial injury was accompanied by reduced mitochondrial outer membrane permeabilization, cytochrome c release and caspase activation. ATO/BSO-induced mitochondrial injury was inhibited by antioxidants. Addition of BSO induced phosphorylation of the pro-apoptotic BCL2 protein, BIM_EL, and anti-apoptotic BCL2 protein, MCL1, in treated cells. Phosphorylated BIM_EL was dissociated from MCL1 and interacted with BAX, followed by conformational change of BAX. Furthermore, the knockdown of BIM_EL with small interfering RNA inhibited the augmentation of ATO-induced apoptosis by BSO.

Conclusions

The enhancing effect of BSO on ATO-induced cell death was characterized at the molecular level for clinical use. Addition of BSO induced mitochondrial injury-mediated apoptosis via the phosphorylation of BIM_EL and MCL1, resulting in their dissociation and increased the interaction between BIM_EL and BAX.

【 授权许可】

   
2014 Tanaka et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Niu C, Yan H, Yu T, Sun HP, Liu JX, Li XS, Wu W, Zhang FQ, Chen Y, Zhou L, et al.: Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 1999, 94(10):3315-3324.
• [2]Mathews V, George B, Lakshmi KM, Viswabandya A, Bajel A, Balasubramanian P, Shaji RV, Srivastava VM, Srivastava A, Chandy M: Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood 2006, 107(7):2627-2632.
• [3]Wang ZY, Chen Z: Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 2008, 111(5):2505-2515.
• [4]Zheng PZ, Wang KK, Zhang QY, Huang QH, Du YZ, Zhang QH, Xiao DK, Shen SH, Imbeaud S, Eveno E, et al.: Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia. Proc Natl Acad Sci U S A 2005, 102(21):7653-7658.
• [5]Jing Y, Dai J, Chalmers-Redman RM, Tatton WG, Waxman S: Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood 1999, 94(6):2102-2111.
• [6]Miller WH Jr, Schipper HM, Lee JS, Singer J, Waxman S: Mechanisms of action of arsenic trioxide. Cancer Res 2002, 62(14):3893-3903.
• [7]Ravandi F, van Besien K: Clinical activity of arsenic trioxide in Burkitt-like lymphoma. Leukemia 2003, 17(1):271-272.
• [8]Akao Y, Yamada H, Nakagawa Y: Arsenic-induced apoptosis in malignant cells in vitro. Leuk Lymphoma 2000, 37(1–2):53-63.
• [9]Wang R, Liu C, Xia L, Zhao G, Gabrilove J, Waxman S, Jing Y: Ethacrynic acid and a derivative enhance apoptosis in arsenic trioxide-treated myeloid leukemia and lymphoma cells: the role of glutathione s-transferase p 1–1. Clin Cancer Res 2012, 18(24):6690-6701.
• [10]Jang M, Kim Y, Won H, Lim S, RJ K, Dashdorj A, Min YH, Kim SY, Shokat KM, Ha J, et al.: Carbonyl reductase 1 offers a novel therapeutic target to enhance leukemia treatment by arsenic trioxide. Cancer Res 2012, 72(16):4214-4224.
• [11]Davison K, Cote S, Mader S, Miller WH: Glutathione depletion overcomes resistance to arsenic trioxide in arsenic-resistant cell lines. Leukemia 2003, 17(5):931-940.
• [12]Maeda H, Hori S, Ohizumi H, Segawa T, Kakehi Y, Ogawa O, Kakizuka A: Effective treatment of advanced solid tumors by the combination of arsenic trioxide and L-buthionine-sulfoximine. Cell Death Differ 2004, 11(7):737-746.
• [13]Han YH, Kim SZ, Kim SH, Park WH: Induction of apoptosis in arsenic trioxide-treated lung cancer A549 cells by buthionine sulfoximine. Mol Cells 2008, 26(2):158-164.
• [14]Takahashi S: Combination therapy with arsenic trioxide for hematological malignancies. Anticancer Agents Med Chem 2010, 10(6):504-510.
• [15]Tobiume K, Saitoh M, Ichijo H: Activation of apoptosis signal-regulating kinase 1 by the stress-induced activating phosphorylation of pre-formed oligomer. J Cell Physiol 2002, 191(1):95-104.
• [16]Negoro E, Yamauchi T, Urasaki Y, Nishi R, Hori H, Ueda T: Characterization of cytarabine-resistant leukemic cell lines established from five different blood cell lineages using gene expression and proteomic analyses. Int J Oncol 2011, 38(4):911-919.
• [17]Lindsten T, Ross AJ, King A, Zong WX, Rathmell JC, Shiels HA, Ulrich E, Waymire KG, Mahar P, Frauwirth K, et al.: The combined functions of proapoptotic Bcl-2 family members bak and bax are essential for normal development of multiple tissues. Mol Cell 2000, 6(6):1389-1399.
• [18]Wei MC, Zong WX, Cheng EH, Lindsten T, Panoutsakopoulou V, Ross AJ, Roth KA, MacGregor GR, Thompson CB, Korsmeyer SJ: Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 2001, 292(5517):727-730.
• [19]Llambi F, Green DR: Apoptosis and oncogenesis: give and take in the BCL-2 family. Curr Opin Genet Dev 2011, 21(1):12-20.
• [20]Shamas-Din A, Brahmbhatt H, Leber B, Andrews DW: BH3-only proteins: orchestrators of apoptosis. Biochim Biophys Acta 2011, 1813(4):508-520.
• [21]Morales AA, Kurtoglu M, Matulis SM, Liu J, Siefker D, Gutman DM, Kaufman JL, Lee KP, Lonial S, Boise LH: Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1-expressing myeloma cells. Blood 2011, 118(5):1329-1339.
• [22]Hubner A, Barrett T, Flavell RA, Davis RJ: Multisite phosphorylation regulates Bim stability and apoptotic activity. Mol Cell 2008, 30(4):415-425.
• [23]Gillings AS, Balmanno K, Wiggins CM, Johnson M, Cook SJ: Apoptosis and autophagy: BIM as a mediator of tumour cell death in response to oncogene-targeted therapeutics. FEBS J 2009, 276(21):6050-6062.
• [24]Gavathiotis E, Suzuki M, Davis ML, Pitter K, Bird GH, Katz SG, Tu HC, Kim H, Cheng EH, Tjandra N, et al.: BAX activation is initiated at a novel interaction site. Nature 2008, 455(7216):1076-1081.
• [25]Kim H, Tu HC, Ren D, Takeuchi O, Jeffers JR, Zambetti GP, Hsieh JJ, Cheng EH: Stepwise activation of BAX and BAK by tBID, BIM, and PUMA initiates mitochondrial apoptosis. Mol Cell 2009, 36(3):487-499.
• [26]Yan W, Arai A, Aoki M, Ichijo H, Miura O: ASK1 is activated by arsenic trioxide in leukemic cells through accumulation of reactive oxygen species and may play a negative role in induction of apoptosis. Biochem Biophys Res Commun 2007, 355(4):1038-1044.
• [27]Matsuzawa A, Ichijo H: Redox control of cell fate by MAP kinase: physiological roles of ASK1-MAP kinase pathway in stress signaling. Biochim Biophys Acta 2008, 1780(11):1325-1336.
• [28]Volynets GP, Chekanov MO, Synyugin AR, Golub AG, Kukharenko OP, Bdzhola VG, Yarmoluk SM: Identification of 3H-naphtho[1,2,3-de]quinoline-2,7-diones as inhibitors of apoptosis signal-regulating kinase 1 (ASK1). J Med Chem 2011, 54(8):2680-2686.
• [29]Davison K, Mann KK, Waxman S, Miller WH Jr: JNK activation is a mediator of arsenic trioxide-induced apoptosis in acute promyelocytic leukemia cells. Blood 2004, 103(9):3496-3502.
• [30]Chen D, Chan R, Waxman S, Jing Y: Buthionine sulfoximine enhancement of arsenic trioxide-induced apoptosis in leukemia and lymphoma cells is mediated via activation of c-Jun NH2-terminal kinase and up-regulation of death receptors. Cancer Res 2006, 66(23):11416-11423.
• [31]Lei K, Davis RJ: JNK phosphorylation of Bim-related members of the Bcl2 family induces Bax-dependent apoptosis. Proc Natl Acad Sci U S A 2003, 100(5):2432-2437.
• [32]Ewings KE, Hadfield-Moorhouse K, Wiggins CM, Wickenden JA, Balmanno K, Gilley R, Degenhardt K, White E, Cook SJ: ERK1/2-dependent phosphorylation of BimEL promotes its rapid dissociation from Mcl-1 and Bcl-xL. EMBO J 2007, 26(12):2856-2867.
• [33]Paterson A, Mockridge CI, Adams JE, Krysov S, Potter KN, Duncombe AS, Cook SJ, Stevenson FK, Packham G: Mechanisms and clinical significance of BIM phosphorylation in chronic lymphocytic leukemia. Blood 2012, 119(7):1726-1736.
• [34]Putcha GV, Le S, Frank S, Besirli CG, Clark K, Chu B, Alix S, Youle RJ, LaMarche A, Maroney AC, et al.: JNK-mediated BIM phosphorylation potentiates BAX-dependent apoptosis. Neuron 2003, 38(6):899-914.
• [35]Lee BC, Park BH, Kim SY, Lee YJ: Role of Bim in diallyl trisulfide-induced cytotoxicity in human cancer cells. J Cell Biochem 2011, 112(1):118-127.
• [36]Soga M, Matsuzawa A, Ichijo H: Oxidative stress-induced diseases via the ASK1 signaling pathway. Int J Cell Biol 2012, 2012:439587.
• [37]Hayakawa R, Hayakawa T, Takeda K, Ichijo H: Therapeutic targets in the ASK1-dependent stress signaling pathways. Proc Jpn Acad Ser B Phys Biol Sci 2012, 88(8):434-453.
• [38]Inoshita S, Takeda K, Hatai T, Terada Y, Sano M, Hata J, Umezawa A, Ichijo H: Phosphorylation and inactivation of myeloid cell leukemia 1 by JNK in response to oxidative stress. J Biol Chem 2002, 277(46):43730-43734.